To identify genomic abnormalities characteristic of pancreatic ductal adenocarcinoma (PDAC) in vivo, a panel of 27 microdissected PDAC specimens were analysed using high-density microarrays representing B116 000 single nucleotide polymorphism (SNP) loci. We detected frequent gains of 1q, 2, 3, 5, 7p, 8q, 11, 14q and 17q (X78% of cases), and losses of 1p, 3p, 6, 9p, 13q, 14q, 17p and 18q (X44%). Although the results were comparable with those from array CGH, regions of those genetic changes were defined more accurately by SNP arrays. Integrating the Ensembl public data, we have generated 'gene' copy number indices that facilitate the search for novel candidates involved in pancreatic carcinogenesis. Copy numbers in a subset of the genes were validated using quantitative real-time PCR. The SKAP2/SCAP2 gene (7p15.2), which belongs to the src family kinases, was most frequently (63%) amplified in our sample set and its recurrent overexpression (67%) was confirmed by reverse transcription-PCR. Furthermore, fluorescence in situ hybridization and in situ RNA hybridization analyses for this gene have demonstrated a significant correlation between DNA copy number and mRNA expression level in an independent sample set (Po0.001). These findings indicate that the dysregulation of SKAP2/SCAP2, which is mostly caused by its increased gene copy number, is likely to be associated with the development of PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging malignancies facing oncologists today. Essentially, no conventional treatment has made a significant impact on the course of the disease, so that the prognosis for patients still remains dismal with a median survival of approximately 6 months from diagnosis and an overall 5-year survival of less than 5% (Jemal et al., 2005) . There is an urgent need for innovative approaches to early diagnosis and specifically targeted therapies, and this will only be made possible by a comprehensive understanding of the molecular events that make this such an aggressively malignant tumour type.
Genomic alterations can contribute to the dysregulation of expression levels of oncogenes and tumour suppressor genes in cancer cells, the accumulation of which is correlated with tumour progression (Ried et al., 1999; Bardeesy and DePinho, 2002; Li et al., 2004; Lips et al., 2007) . The introduction of genotyping by single nucleotide polymorphism (SNP) arrays has allowed genome-wide, high-resolution analysis of both DNA copy number (DCN) alterations and loss of heterozygosity (LOH) events in cancer cells (Lindblad-Toh et al., 2000; Bignell et al., 2004; Huang et al., 2004; Janne et al., 2004; Zhao et al., 2004 Zhao et al., , 2005 Midorikawa et al., 2006) . High-density SNP microarrays permit highly accurate mapping of those genetic changes across the entire genome, providing a promising starting point for the identification of novel candidate genes affected by such genomic abnormalities. In the present study, to identify genomic changes characteristic of PDAC cells in vivo, we analysed a panel of 27 microdissected PDAC tissue samples using the Affymetrix 100 K SNP arrays. Based on the obtained DCN data, we found a novel candidate gene, SCAP2 (SKAP2 is the latest official gene symbol), which is located at the minimal overlapping region of 7p15.2 gain. The general applicability of this observation was prospectively validated in an independent sample set using fluorescence in situ hybridization (FISH) and in situ RNA hybridization (ISH).
Results
Genome-wide analysis of DCN alterations in PDAC cells in vivo Genome-wide copy number analysis was performed in a total of 27 microdissected PDAC samples (Supplementary Table 1 ). The average genotype call rate was 96.3 ± 3.4 and 97.0 ± 2.3% in HindIII and XbaI 50K SNP arrays, respectively. All the raw data are available in the Gene Expression Omnibus (GEO) (http://www.ncbi. nlm.nih.gov/geo/) with the accession number GSE7130.
The Copy Number Analyzer for Affymetrix GeneChip (CNAG) analysis for all 27 PDAC samples identified chromosomal regions of both DCN alterations and LOH throughout the whole genome of PDACs. We summarize genetic abnormalities of all chromosomes in Figure 1 . (All the details including published copy number variation (CNV) data are shown in Supplementary Figure 1) The most frequent genetic gain was detected on 8q in our sample set (26 out of 27 cases; 96%). Gains of 1q, 2, 3, 5, 7p, 11, 14q and 17q were also identified at a high frequency (X78% of cases). On the other hand, the most recurrent genetic loss was observed on 9p in 21 out of 27 cases (78%), followed by 18q, 6, 1p, 13q, 17p, 3p and 14q (X44% of cases). Overall, the spectrum patterns of genetic changes identified by SNP arrays were similar to our previous results from both metaphase and array-based comparative genomic hybridization (array CGH) (Harada et al., 2002a (Harada et al., , b, 2007 . However, with the increased resolution, SNP arrays delineated more precise physical boundaries of chromosomal breakpoints in PDAC ( Figure 2) . As a result, we have identified homozygous deletions at 9p21.3 (45 kb) and high-level amplifications in three regions of 8q: 8q24.13-q24.21 (2.2 Mb), 8q24.22 (177 kb) and 8q24.23-q24.3 (2.7 Mb) (X19% of cases). These were detected as minimal regions of frequent genetic alterations and therefore, considered to be epicentres in those changes (Supplementary Figure 1) . DCN alterations in individual genes across the entire genome By integrating the Ensembl public data with our DCN data, we sought to identify 'gene' copy numbers throughout the entire genome of PDAC. We have documented the genes included in regions of frequent genetic changes in Table 1 and the complete list of copy  numbers in all the genes is provided in Supplementary  Table 2 . These gene copy number indices enabled comparison of our results with the previously published data. SCAP2 (SKAP2, 7p15.2) was identified as the Figure 1 The overview of genomic changes of all chromosomes in a total of 27 microdissected PDAC tissues, determined by the Affymetrix 100 K SNP arrays. (see Supplementary Figure 1 for all the details) 'Genetic gains' are shown as green bars and 'losses' as red bars according to the genomic position (Build 35). Thick bars are used to depict 'high-level amplifications' and 'homozygous deletions'. Blue bars indicate 'LOH regions' and grey, thick bars are used for 'UPD regions'.
Genome-wide analysis in pancreatic cancer T Harada et al most frequently (63% of cases) amplified gene in 27 PDACs, which has not been described in any type of cancer. We also detected increased copy numbers in MYC (8q24.21, 48%), NCOA3/AIB1 (20q13.12, 44%), KRAS (12p12.1, 44%), ERBB2 (17q12, 41%) and EGFR (7p11.2, 33%) genes. On the other hand, two tumour suppressor genes, CDKN2A and CDKN2B, were included in the locus of 9p21.3 that was deleted at the highest frequency (63% of cases). Genetic losses were also detected in genes such as DCC (18q21.1, 48%), SMAD4 (18q21.1, 33%), MAP2K4 (17p12, 30%), TP53 (17p13.1, 26%) and RUNX3 (1p36.11, 22%). Thus, recurrent genetic changes that were previously characterized in PDAC were commonly observed in our analysis (Bardeesy and DePinho, 2002; Li et al., 2004) . Table 4 ).
Screening for genes within the minimal amplicon at 7p15.2 region by reverse transcription-PCR SNP arrays enabled us to narrow down the minimal overlapping regions of DCN alterations, which are likely to contain critical oncogenes or tumour suppressor genes. In this study, we identified frequent gains on 7p in 27 PDAC cases (78%). Although 7p copy number gain has been detected as a large region, our array results revealed the minimal region at 7p15.2, with X3 copies found in 59-63% of cases ( Figure 4A ). According to the Ensembl database, this region is approximately 1 Mb in size and includes five known genes (NFE2L3, HNRPA2B1, CBX3, SNX10 and SCAP2). This region was not involved in CNV regions and therefore, thought to be 'acquired' alteration (Supplementary Figure 1) (Redon et al., 2006) . We postulated that some of these genes may be incidentally coamplified due to the ongoing genomic instability, along with the target gene(s). To screen for the gene(s) whose DCN alteration(s) could lead to significant change(s) in transcript level, reverse transcription-PCR (RT-PCR) was performed for five candidate genes within this amplicon ( Figure 4B ). The transcripts of four genes (NFE2L3, HNRPA2B1, CBX3 and SNX10) were expressed in normal pancreas tissues, whereas various levels Genome-wide analysis in pancreatic cancer T Harada et al Genome-wide analysis in pancreatic cancer T Harada et al of expression were observed in PDAC cases. In contrast, SCAP2 was the only gene that was not expressed in normal tissues, but it was upregulated in eight out of 12 PDAC cases (67%). These results raised the possibility that genetic gain of this region could be caused solely by the SCAP2 gene.
A strong correlation between DCN and mRNA expression level of SCAP2 To validate the high frequency of SCAP2 gain, interphase FISH analysis was applied to an independent sample set that consists of 92 PDAC cases (see Materials and methods). However, we used 36 cases for the analysis because the remaining 56 specimens were not interpretable probably due to formalin overfixation of tissues (Table 2) . DCN of the SCAP2 gene was increased in 19 out of 36 PDAC tissues (53%), which was a similar frequency to the DCN data by SNP arrays ( Figure 4C ). Next, to evaluate further the frequency of SCAP2 overexpression, ISH was carried out using all PDAC tissues except for one damaged tissue ( Figure 4D ). In normal pancreas and liver tissues, there was no SCAP2 expression detected in ductal, islet and hepatic cells, whereas very subtle, patchy signals were observed in acinar cells. In contrast, the SCAP2 transcript was upregulated (score 1-2) in 62 out of 91 PDAC cases (68%), which was in good accordance with the RT-PCR results (Supplementary Table 5 ). Moreover, SCAP2 overexpression was observed consistently from early-(I-II) to late-stage (III-IVb) tumours, indicating that this gene may be involved in the development of PDAC. Finally, in order to assess directly whether an increased gene copy number of SCAP2 is associated with overexpression of its transcript, we compared the FISH and ISH results from 36 PDAC tissues that were commonly used for both analyses ( The number of cases in which low-level gain (DCN ¼ 3 or 4) was observed.
c The number of cases in which high-level amplification (DCNX5) was observed. d Total number of regions in which a gene copy number was decreased.
e The number of cases in which hemizygous deletion (DCN ¼ 1) was observed.
f The number of cases in which homozygous deletion (DCN ¼ 0) was observed. Figure 3 Comparison of DCN alterations identified by SNP arrays (blue columns) and q-PCR (violet columns) analyses. A significant correlation (r ¼ 0.72) was observed between two data sets. All the data are shown in Supplementary Table 3 .
Genome-wide analysis in pancreatic cancer T Harada et al number and expression level of this gene (Po0.001, Fisher's exact test).
Discussion
It is well known that PDAC tissues are especially heterogeneous, with neoplastic cells constituting only a small proportion of the tumour mass. Previous studies have shown that the quality of the data from SNP arrays is highly dependent on tumour purity: Up to 20% of contamination with non-neoplastic cells should be acceptable for the detection of genomic abnormalities, whereas more than 30% of contamination resulted in a significant reduction of the sensitivity of the analysis Genome-wide analysis in pancreatic cancer T Harada et al Andersen et al., 2007) . In the present study, we applied only microdissected samples to Affymetrix 100 K SNP arrays, which was crucial to identify genetic changes that reflect the intrinsic characteristics of PDAC cells in vivo at a high sensitivity. In addition, integrating the Ensembl public data with our results, we identified copy number changes in individual genes across the entire genome (Supplementary Table 2 ). The 'gene' copy number indices we provide here facilitate the search for novel candidate genes that may be useful as potential diagnostic and prognostic markers. Copy numbers in a subset of the genes were then validated by q-PCR to prove the relevance of our DCN data from SNP arrays. Analysing matched normal DNA in parallel with tumour DNA, SNP arrays can be a powerful tool for the genome-wide detection of LOH/UPD regions because we could completely exclude consanguinity as a cause of homozygosity (Fitzgibbon et al., 2005; Raghavan et al., 2005; Andersen et al., 2007) . However, the use of microdissected tumour samples is thought to be advantageous for more accurate determination of LOH regions in case constitutive DNA is not available (Yamamoto et al., 2007) . We found that approximately 40% of LOH regions were considered to be UPD in PDAC tissues, whereas a previous study has shown that UPD was detected in almost 50% of LOH regions using 26 PDAC-derived cell lines (Calhoun et al., 2006) . Accordingly, this copy-neutral event is likely to occur frequently in PDAC cells in vivo as well as in vitro. Interestingly, we found that common UPD regions were preferentially observed in only three chromosome loci, indicating that these UPD events may be nonrandom. Our previous study has shown that UPD in acute myeloid leukaemia can result in homozygosity for gene mutations (Fitzgibbon et al., 2005) . Therefore, we speculate that common UPD regions in PDAC may harbour genes that are targets for somatic mutations (Supplementary Table 4) .
Chromosome arm 7p has long been suspected to include critical oncogenes in PDAC (Griffin et al., 1995; Harada et al., 2002a; Karhu et al., 2006) . Our SNP array analysis has revealed the minimal common region (7p15.2) of 7p gain, which was most frequently (approximately 60%) identified in 27 PDAC cases ( Figure 4A ). Among five known genes included in this region, SCAP2 was the only gene to show the possibility of a causal relationship between gene dosage and mRNA expression level. Therefore, we hypothesized that SCAP2 may potentially be the 'driver' gene in a frequently observed gain of this 1 Mb region.
In order to evaluate this hypothesis, we performed FISH and ISH analyses on the identical tissue specimens, which allowed for the direct comparison between DNA and mRNA status of SCAP2 in vivo. Our FISH results have shown a genetic gain of SCAP2 in 53% of another population of 36 PDAC cases, which was a similar frequency to those from SNP arrays (63%). These findings demonstrate that an increased DCN of SCAP2 could be a prevalent genetic change in the majority of PDAC cases. More importantly, there was a significant correlation (Po0.001) between genetic gain and overexpression of the SCAP2 gene, suggesting that the transcript level of this gene may be regulated by its DNA copy number. High-level amplification of SCAP2 was not frequent in our sample set, but it is known that even a low-level copy number change can have a significant effect on gene expression in cancer (Chin et al., 2006; Saramaki et al., 2006) . SCAP2 was first identified as a cancer-related gene by Buchholz et al., showing that this gene is overexpressed in pancreatic intraepithelial neoplasia (PanIN) lesions (Buchholz et al., 2005) . The present study has shown that SCAP2 is upregulated in PDAC tissues at a high frequency (67 and 68% in RT-PCR and ISH, respectively). Furthermore, we found that a genetic gain of SCAP2 was frequently observed in PDAC tissues using both CGH and SNP arrays as well as FISH (Harada et al., 2007) . Taken together, the dysregulation of SCAP2, which is mostly caused by its increased gene copy number, is -42, 44, 46, 48-49, 51-55) in this table has been reported in our previous manuscript (Table 4 in ref. Harada et al., 2007) . d Significant differences are outlined in bold. All ISH results are shown in Supplementary Table 5 .
Genome-wide analysis in pancreatic cancer T Harada et al likely to be associated with the development of PDAC. SCAP2 was originally described as a substrate for the src family kinases able to regulate the phosphorylation of the presynaptic protein a-Synuclein; a process considered to be crucial in the pathogenesis of several neurodegenerative diseases including Parkinson's disease (Takahashi et al., 2003) . Although SCAP2 structurally seems to be an adaptor protein with a SH3 domain providing a binding site for the focal adhesion kinase RAFTK, the biological role of this gene is still unknown. However, based on the ability of SCAP2 to interact with RAFTK, it is likely to modulate the spreading and motility of PDAC cells (McLean et al., 2005) . Interestingly, a recent study has demonstrated that overexpression of a-Synuclein in osteosarcoma cells results in a prolonged G 1 phase of the cell cycle and initiates tumour differentiation (Fujita et al., 2006) . Therefore, we speculate that SCAP2 could also control the growth and differentiation of PDAC cells. This hypothesis is supported by the data that SCAP2 is overexpressed in PanIN lesions as well as in PDACs. Based on these observations, we propose that SCAP2 could be a potential marker gene for early diagnosis and a possible target for therapeutic intervention in PDAC.
Materials and methods
Tumour and reference samples A total of 27 fresh-frozen PDAC tissue specimens were obtained surgically or at autopsy from Yamaguchi University School of Medicine, Japan (Supplementary Table 1 ). Tissue microdissection was manually performed to collect tumour cells at more than 90% purity in all cases, and DNA was extracted as described previously (Harada et al., 2002a) . Reference DNA was obtained from lymphocytes of a total of 13 healthy volunteers (6 males and 7 females) whose ethnicity is anonymous. These tumour and reference genomic DNAs were used for both SNP array and q-PCR analyses.
Another series of 12 fresh-frozen PDAC and two normal pancreas tissues were obtained from the Human Biomaterials Resource Centre, Department of Histopathology, Charing Cross Hospital, London, UK, and were subjected to RT-PCR. The clinicopathological information was not available for these anonymous samples. In addition, an independent sample set of 92 formalin-fixed, paraffin-embedded PDAC tissue sections (4-5 mm thickness) were prepared for FISH and ISH analyses: 25 samples from Yamaguchi University and 67 samples from a tissue microarray (US Biomax Inc., Rockville, MD, USA; http://www.biomax.us/tissue-arrays/Pancreas/ PA801). All the clinical samples were obtained with ethical approval of the host institutions. This study was approved by a Research Ethical Committee (REC) with the REC Project Number 05/80408/6S.
Affymetrix 100 K SNP arrays and data analysis We used the GeneChip Human Mapping 100 K Set (Affymetrix, Santa Clara, CA, USA) that is composed of two 50 K arrays (Hind240 and Xba240). DNA digestion, labelling and hybridization were performed according to the manufacturer's instructions as described elsewhere (Zhao et al., 2005) . The raw images were analysed using the GCOS (Ver1.4) and GTYPE (Ver4.1) software (Affymetrix).
To assess DCN alterations and LOH, we used the CNAG (Ver2.0) software (http://www.genome.umin.jp/) (Nannya et al., 2005) . We chose 'automatic analysis' mode in which the software performs pair-wise tests using all the references. 'Genetic gains' (DCNX3) and 'losses' (DCNp1) were defined according to working criteria of CNAG. In addition, 'highlevel amplifications' and 'homozygous deletions' were determined to be DCNX5 and DCN ¼ 0, respectively. In order to avoid false-positive changes due to random noise in signal intensity at each SNP, we set a minimum physical length of at least five consecutive SNPs for putative genetic alterations. The LOH data from two 50 K chips were analysed separately and both results were then merged to determine LOH regions. Chromosome X was not analysed to avoid gender-related complications (Andersen et al., 2007) . UPD regions were defined as LOH regions without DCN alterations.
Gene annotation and data integration
The physical position of all SNPs (n ¼ 116 204) on the arrays was mapped according to the Human Genome Sequence (Build 35). We developed our own visualization software to merge all genetic aberrations with the gene annotation from the Ensembl Ver.37 (the most updated version based on Build 35) (http://www.ensembl.org) public database. Taking structural variation in the human genome into account, our software integrated the public data of CNVs (http://projects. tcag.ca/variation/) into our analysis (Iafrate et al., 2004; Redon et al., 2006) .
DCN alterations determined by q-PCR
Relative gene copy numbers were determined by q-PCR using the ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Cheshire, UK) and a TaqMan Universal PCR Master Mix kit (Applied Biosystems), as described previously, with minor modifications (Zhao et al., , 2005 . PCR condition as well as primers and TaqMan MGB probes sequence for five genes (FN1, SCAP2, RAB2, CDKN2A and HAND1) are available in Supplementary Table 6 . PCR reactions were performed in triplicate for each primer set and the data were analysed using the Sequence Detection Software Ver1.3 (Applied Biosystems). Each tumour DNA was quantified by comparing the target locus to the reference locus of the HAND1 gene (5q33.2), for which DCN of 2 was confirmed by SNP arrays in all 19 samples analysed. The standard curve method was used to calculate target gene copy number in the tumour DNA sample normalized to the reference gene (HAND1) and calibrated to normal DNA.
Reverse transcription-PCR RT-PCR was performed using 12 PDAC and two normal pancreas tissues, as described previously (Harada et al., 2007) . cDNAs were synthesized from 1 mg of total RNA using an oligo (dT) primer. Reverse transcription was followed by 30 PCR cycles to amplify a cDNA fragment of each of five genes (NFE2L3, HNRPA2B1, CBX3, SNX10 and SCAP2). 18S rRNA was used as an endogenous control. All the primer sets used are shown in Supplementary Table 6 . Amplified products were separated on 1% agarose gels and visualized with ethidium bromide.
Two-colour FISH for SCAP2 Two-colour FISH was performed as described previously (Harada et al., 2007) . The target probe was prepared from the BAC clone, RP11-232C20 (BACPAC Resources, Oakland, CA, USA) including the SCAP2 gene and its DNA was labelled with Cy3-dCTP. Centromeric probes for chromosomes 7 (CEP7) labelled with SpectrumGreen were purchased from Vysis (Downers Grove, IL, USA). The threshold of gain and loss was defined as ratios (BAC/centromeric probes) of X1.16 and p0.87, respectively, corresponding to ± 2 standard deviation (see Harada et al., 2007 for more details).
ISH for SCAP2
The SCAP2 probe was amplified by PCR from OriGene clone TC117697 (OriGene Technologies Inc., Rockville, MD, USA) that encodes full-length cDNA of SCAP2. The primers used to amplify SCAP2 product are the same as those used in RT-PCR (Supplementary Table 6 ). The PCR product was cloned into the pCR4-TOPO vector using the TOPO cloning kit (Invitrogen Ltd, Paisley, UK) to create pCR4-SCAP2-ISH. Positive clones were verified by sequence analysis. Riboprobes were synthesized from 1 mg of linearized pCR4-SCAP2-ISH plasmid DNA and digoxigenin were labelled using a DIG RNA labelling kit (Roche Diagnostics, Mannheim, Germany). T3 and T7 polymerases were used to synthesize anti-sense and sense probes, respectively. Riboprobes for SCAP2 (30 ng per case) were hybridized to PDAC tissues using the Ventana Discovery System (Ventana Medical Systems, Tucson, AZ, USA). SCAP2 mRNA expression was judged using a 0-2 score (0 ¼ no signal, 1 ¼ weak intensity, 2 ¼ strong intensity).
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